Recently, another traditional pharmaceutical company and Biotech announced a merger and acquisition! Guilin Sanjin recently announced that the company intends to become the largest shareholder of Shanghai Saijin and relatively controlling the company by paying cash and all the shares of its wholly-owned Sun company
Baojian Biotechnology.
For the purpose of this acquisition, Guilin Sanjin said that it is to expand the company's industrial layout in the field of biomedicine, effectively integrate the company's biomedical resources, enhance the research and development capabilities and competitiveness in the field of biomedicine, and accelerate the company's development
in the field of biomedicine.
According to the data, Guilin Sanjin is mainly engaged in the research and production of traditional Chinese medicine and natural medicine, and its wholly-owned Sun company Baozhou Biotechnology is mainly developing anti-cancer drugs, focusing on the field of digestive tract tumors, and there are no products on the market at present, but PD-L1, EGFR monoclonal antibody products are in the phase II clinical stage, and there are CD47, CSF-1R, CLDN18.
2 and other popular targets under study
.
The R&D pipeline of Shanghai Saijin products to be acquired by the company is relatively rich, covering a variety of biosimilars and bioinnovative drugs in the field of autoimmune diseases and malignant tumors, mainly focusing on the field of
autoimmune system.
It is reported that Guilin Sanjin hopes that through this investment, the R&D pipelines of the two companies will complement each other, effectively integrate biomedical resources, combine the advantages of industrialization with the front-end R&D advantages of Shanghai Saijin, and give full play to the synergy effect of 1+1>2
.
From the perspective of the industry background, in recent years, with the normalization of centralized procurement, consistency evaluation and other medical reform policies, the innovation and transformation of the pharmaceutical industry has become a trend, in order to accelerate the transformation, traditional pharmaceutical companies and Biotech cooperation mergers and acquisitions have also become the norm
.
Among them, commercialization cooperation is the main form of
cooperation between traditional pharmaceutical companies and Biotech.
For example, on June 23, 2022, YOFOTO Guojian announced that it has licensed the global rights of enitumab (trade name: Septin) antibody sequences for the development and commercialization of antibody conjugates (ADCs) to Chengdu Kelingyuan Pharmaceutical, a wholly-owned subsidiary of Chengdu Xilingyuan Pharmaceutical
.
Sihuan Pharmaceutical, a large domestic pharmaceutical and medical beauty group, controlled Xuanzhu Biotechnology in 2008 and completed the wholly-owned acquisition
of Xuanzhu in 2012.
At present, Xuanzhu has established two innovative drug research and development platforms of small molecule and large molecule, and has relatively complete preclinical development capabilities
.
On June 16, 2022, Sihuan Pharmaceutical announced that its subsidiary Xuanzhu Biotech entered into a licensing agreement with Shanghai Pharmaceutical's subsidiary Shanghai Pharmaceutical New Asia to reach an exclusive license
with Shanghai Medicine Xinya for its two anti-infective new drug products, Bainapenem and Plazomicin APIs and preparations, in Greater China.
.
.
.
.
.
.
.
The analysis believes that it is difficult for traditional pharmaceutical companies to rely on their own transformation, because most traditional pharmaceutical companies lack the foundation of innovative drugs, do not have the ability to develop new drugs, and the time and manpower required to make innovative drugs by themselves are all challenges, and through cooperation with Biotech, you can quickly enter the innovative drug market
.
In addition, with the help of new technologies and new concepts possessed by Biotech, it is also conducive to accelerating the transformation of traditional pharmaceutical companies
.
Biotech lacks clinical and market resources, and on the basis of strong innovation capabilities, it can achieve a win-win situation by cooperating with traditional pharmaceutical companies and obtaining the support of strong channels and medical resources of traditional pharmaceutical companies
.
According to relevant statistics, in the first half of 2022, Biotech actively chose to cooperate with domestic traditional pharmaceutical companies, and the number of domestic BD transactions increased by 61.
52%
compared with last year.
The industry expects that with the gradual deepening of the cooperation demand between traditional pharmaceutical companies and Biotech, it is expected that the cooperation between traditional pharmaceutical companies and Biotech will become the main theme
of the industry in the next 2-3 years.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
